Sentry Investment Management LLC maintained its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,924 shares of the medical equipment provider’s stock at the close of the 2nd quarter. Sentry Investment Management LLC’s holdings in Zimmer Biomet Holdings were worth $1,659,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ZBH. Bronfman E.L. Rothschild L.P. lifted its position in shares of Zimmer Biomet Holdings by 25.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after acquiring an additional 167 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of Zimmer Biomet Holdings by 3.9% during the 2nd quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after purchasing an additional 33 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Zimmer Biomet Holdings by 20.8% during the 1st quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after purchasing an additional 199 shares in the last quarter. IHT Wealth Management LLC increased its stake in shares of Zimmer Biomet Holdings by 28.4% during the 1st quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after purchasing an additional 256 shares in the last quarter. Finally, BB&T Investment Services Inc. purchased a new position in shares of Zimmer Biomet Holdings during the 2nd quarter worth approximately $144,000. Institutional investors own 85.22% of the company’s stock.

In related news, VP Tony W. Collins sold 16,986 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.07% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/18/sentry-investment-management-llc-continues-to-hold-stake-in-zimmer-biomet-holdings-inc-zbh.html.

A number of research analysts have recently weighed in on the stock. Royal Bank Of Canada reissued an “outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Wells Fargo & Company reissued a “market weight” rating on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Jefferies Group LLC reissued a “buy” rating and set a $148.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, June 30th. Oppenheimer Holdings, Inc. set a $137.00 price objective on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a research note on Friday, July 28th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $135.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 28th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Zimmer Biomet Holdings presently has a consensus rating of “Hold” and an average target price of $136.55.

Zimmer Biomet Holdings, Inc. (NYSE ZBH) traded up 0.16% on Wednesday, reaching $120.12. 209,966 shares of the company’s stock traded hands. The stock has a market capitalization of $24.29 billion, a PE ratio of 34.21 and a beta of 1.19. The firm’s 50-day moving average is $116.07 and its 200 day moving average is $120.38. Zimmer Biomet Holdings, Inc. has a 52-week low of $95.63 and a 52-week high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.10 by ($0.02). The firm had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The company’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter last year, the business earned $2.02 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.23 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date of this dividend is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is currently 27.59%.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.